Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's average EBITDA Per Share Growth Rate was -6.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 28.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 30.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents 3-Year EBITDA Growth Rate Related Terms
CAI:RMDA vs ZTS, UTHR, VTRS: 3-Year EBITDA Growth Rate Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 28.20% mean?
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) has a 3-Year EBITDA Growth Rate of 28.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents and its competitors. This is near median its historical median of 26.30. Over the past decade, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' 3-Year EBITDA Growth Rate has ranged from 10.90 to 35.30. According to the industry distribution chart, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ranks #187 out of 808 companies in the Drug Manufacturers industry, placing it in the top 23.1%.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' 3-Year EBITDA Growth Rate too high?
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' current 3-Year EBITDA Growth Rate of 28.20% is near median its 10-year median of 26.30. Over the past 10 years, this metric has ranged from a low of 10.90 to a high of 35.30. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' value of 28.20% is 216.9% above this industry median. Based on the distribution chart, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ranks #187 out of 808 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents ranks #187 out of 808 companies for 3-Year EBITDA Growth Rate. This places Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents in the top 23% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' value of 28.20% is 216.9% above this benchmark. Historically, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' own 3-Year EBITDA Growth Rate has ranged from 10.90 to 35.30 over the past decade. While the company's 10-year median is 26.30 vs. the industry median of 8.90, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's current 3-Year EBITDA Growth Rate of 28.20% is 216.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's current 3-Year EBITDA Growth Rate is 28.20%, which is near median its own 10-year median of 26.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents stock overvalued right now?
Based on GuruFocus' analysis, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) is currently considered Modestly Overvalued. The stock's GF Value™ is E£5.20, compared to a current price of E£6.10 — trading 17.3% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 28.20%, which is near median its 10-year median of 26.30 and 216.9% above the Drug Manufacturers industry median of 8.90. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents' overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA), the current 3-Year EBITDA Growth Rate is 28.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Overvalued in 2026?
Based on GuruFocus' analysis, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents stock appears to be overvalued.
The current stock price of E£6.10 is trading 17.3% above its estimated GF Value™ of E£5.20.
GuruFocus considers Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents to be Modestly Overvalued.
Key valuation signals for CAI:RMDA:
3-Year EBITDA Growth Rate: 28.20% (near median its 10-year median of 26.30)
GF Value™: E£5.20 vs. price of E£6.10 (17.3% above fair value)
Industry Position: 216.9% above the Drug Manufacturers median (#187 of 808)
No single metric tells the full story. See the CAI:RMDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents is a pharmaceutical company. The company is engaged in the Manufacturing, marketing, selling and storing of pharmaceutical reagents for human and veterinary use; manufacturing, marketing, selling and storing of diagnostic reagents necessary for individuals, laboratories and hospitals; importing pharmaceutical reagents and raw materials necessary for serving the its purposes without trading; producing pharmaceutical reagents for human and veterinary and diagnostic use for others and by others; and producing food supplements for human use for others and by others. It has two segments: production and selling of pharmaceutical products, which generates maximum revenue; and manufacturing for others (Toll manufacturing).
86GF Score
Get the complete analysis for CAI:RMDA
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:RMDA has been successfully added to your 
